Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tomivosertib |
Trade Name | |
Synonyms | eFT508|EFT-508 |
Drug Descriptions |
Tomivosertib (eFT508) inhibits MNK1 and MNK2, potentially resulting in decreased tumor cell proliferation and tumor growth, and disrupts translation of PD-L1 (CD274) through inhibition of EIF4E phosphorylation (PMID: 30643286). |
DrugClasses | MNK1/2 Inhibitor 3 |
CAS Registry Number | 1849590-01-7 |
NCIT ID | C125062 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + Tomivosertib | Avelumab Tomivosertib | 0 | 1 |
Azacitidine + Tomivosertib + Venetoclax | Azacitidine Tomivosertib Venetoclax | 0 | 1 |
Paclitaxel + Tomivosertib | Paclitaxel Tomivosertib | 0 | 1 |
Pembrolizumab + Pemetrexed Disodium + Tomivosertib | Pembrolizumab Pemetrexed Disodium Tomivosertib | 0 | 1 |
Pembrolizumab + Tomivosertib | Pembrolizumab Tomivosertib | 0 | 1 |
Tomivosertib | Tomivosertib | 0 | 6 |